In this episode, Joe Moore interviews Christopher Dawson & Andrew Galloway: Co-Founders and CEO and COO, respectively, of Dimensions; a Canadian-based company creating retreats that blend traditional plant ceremonies with neuroscience and a luxurious, five-star environment. They each tell their story and how it led to the beginnings of Dimensions, where they worked for a year with a “Dreamlab” team of MDs, psychiatrists, practitioners from different fields, and even a design agency to create different programs for different substances – all with a focus on true set and setting and integrating perfectly with nature. They talk about Health Canada and the country’s trajectory towards legal psychedelics; critiques of traditional addiction treatment and the efficacy of 12-step programs; the tension between the psychedelic space and traditional healing space; investing in biotech; the polyvagal theory; how animals deal with trauma (and how we don’t); and the concept of integration: If you’re just taking a pill and not doing the work, are you missing the point entirely?

The post PT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant Medicine With Neuroscience and Luxury appeared first on Psychedelics Today.

Previous articleTripping the Reward Circuit: Psychedelics for Substance Use Disorders
Next articleFILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL